Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

During the past decade new development in hepatitis research have shed new light on the etiologic, epidemiologic, immunologic, and prophylactic aspects of type A and B hepatitis virus infection. Recent advances in hepatitis A virus research include: (1) identification of the virus as a 27 nm particle with characteristics resembling an enterovirus, (2) transmission of the infection to marmosets and chimpanzees, and (3) development of specific complement fixation and immune adherence antibody tests. Recent advances in hepatitis B research include: (1) identification of the virus as a 42 nm particle (Dane particle) containing an outer coat, the hepatitis B surface antigen, and an inner core, the hepatitis B core antigen, (2) development of specific tests to detect the hepatitis B antigens and their respective antibodies, (3) transmission of the infection to chimpanzees, (4) development of a specific hepatitis B immune serum globulin, and (5) development of an inactivated hepatitis B vaccine.
 ...
PMID:Viral hepatitis: recent developments and prospects for prevention. 17 63

Eleven of 40 patients in a hemodialysis unit had clinical or biochemical evidence of hepatitis during a five-week period. The clinical disease was mild, being limited solely to dialysis patients. Epidemiologic investigation indicated that the incubation period was between 17 and 35 days and that 10 of 11 patients had been exposed to a single venous-pressure monitor before onset. Dried blood and evidence of blood reflux up the venous-pressure gauge suggested that cross-contamination of the blood of successive patients probably resulted in transmission of disease. No association with the hepatitis B surface antigen or anti-hepatitis B antibody was demonstrated, but 10 of the 11 patients with elevated transaminase levels had evidence of recent exposure, to Epstein-Barr virus as manifested either by Ox-cell hemolysin titers or rises in titers to viral capsid antigen.
 ...
PMID:HBs-Ag-negative hepatitis in a hemodialysis unit: relation to Epstein-Barr virus. 17 73

We have induced hepatitis A in marmosets of the subspecies Saguinus mystax following primary inoculation with human serum containing the MS-1 strain of hepatitis A virus (HAV) and in 3 further marmoset subpassages using infective marmoset serum from each preceding passage. In each passage acquisition of serum antibody against 17 nm virus-like particles recovered from acute illness stools of human volunteers who developed hepatitis following inoculation with the MS-1 strain of HAV, as well as from acute illness stools of hepatitis A cases from a common source epidemic of heaptitis A in Arizona could be demonstrated by immune electron microscopy (IEM). Particle-containing stool filtrates from the latter epidemic also induced hepatitis in chimpanzees after intravenous inoculation. Inoculation of partially purified particles from a single banding in CsCl2 has further resulted in the induction of hepatitis in S. mystax marmosets. We have successfully induced hepatitis in a series of chimpanzees inoculated with sera containing hepatitis B surface antigen (HBsAg) of varying subspecificities. Susceptibility appears universal in animals who are initially lacking in serum antibody (anti-HBs) and antibody induced following experimental infection is homologous in subspecificity to the subspecificities of the antigenic coat components of the HBsAg in the inoculum. Results of cross challenge experiments indicate that animals developing hepatitis following inoculation of HBsAg of one subspecificity set in the d/y-w/r system do not again develop hepatitis following inoculation with HBsAg of the alternate subspecificity set.
 ...
PMID:Infectivity studies of hepatitis A and B in non-human primates. 17 99

Sera from 627 students entering Colleges of Education between 1969 and 1972 were tested for hepatitis B surface antigen and antibody. One was found positive for antigen, none for antibody. Six for 15 positive Hepanosticon results and two positive Hepatest results occurred in sera which also gave positive heterophil antibody tests indicative of current or recent EB virus infection. One of these six sera was still positive in the Hepanosticon test after one absorption, and one of two Hepatests gave no positive reaction with the control cells. Eleven of 14 sera from cases of infectious mononucleosis gave positive Hepanosticon results and two were still positive after one absorption. Seven were positive in the Hepatest and only three of these were positive with the control cells. The control tests in the Hepanosticon and Hepatest do not clearly identify all false positives due to Paul Bunnell antibody. It is suggested that when a positive result in a passive haemagglutination test can be removed by absorption or if positive after absorption cannot be confirmed by other tests for hepatitis Bs antigen, the patient from whom the serum specimen was taken should be investigated for indications of current EB virus infection.
 ...
PMID:Screening tests for hepatitis B antigen and antibody in two colleges of education and studies on the relationship between nonspecific positive antibody tests and EB virus infection. 18 37

The development of cell-mediated immunity (CMI) to the surface antigen of hepatitis B virus (HBSAg) and Botevgrad antigen (BA) was traced in 50 hepatitis patients. Migration inhibition test (MIT) was performed with purified HBSg and AB. Blood samples from every hepatitis patient were obtained at the beginning of the icteric phase, 10 days later and during convalescence. There was correlation between the two types of viral hepatitis and the type of cellular immune response. The development of CMI is associated with disappearance of HBSAg from the serum of hepatitis patients. CMI to HBSAg develops within 9-12 days after the onset of icterus and to BA during the first two days of icterus. There is a relationship between the persistence of HBSAg and CMI.
 ...
PMID:[Development of cellular immunity in patients with viral hepatitis]. 18 10

Significant liver disease developed in 14 patients after renal transplantation. Nine patients had morphologic and functional evidence of chronic active hepatitis. In general, these patients had few symptoms of liver disease, even though the course of chronic active hepatitis was progressive. Despite large doses of prednisone, cirrhosis ultimately developed in five patients. The cause of chronic active hepatitis could not be related to azathioprine or methyldopa therapy because there was no perceptible change in the course of liver disease after treatment with these drugs was stopped. Three patients were persistently positive for hepatitis B surface antigen. Isolated instances of granulomatous hepatitis (Mycobacterium kansasii) and of prolonged intrahepatic cholestasis were encountered in patients with chronic active hepatitis. Two patients had acute cytomegalovirus hepatitis. There was one episode each of fulminant herpes simplex hepatitis and severe fatty metamorphosis.
 ...
PMID:Liver disease in renal transplant recipients. 18 93

In studies conducted in the early 1950s, sera from six asymptomatic blood donors, implicated in the transmission of viral hepatitis, were inoculated into 10 to 20 volunteers each. Five of these "implicated" donor sera transmitted clinically apparent hepatitis to the recipients. The stored serum samples from these studies have been reanalyzed using serologic markers for hepatitis B virus and hepatitis A virus infection. Two of the donor sera were hepatitis B surface antigen (HBsAg)-positive, and both transmitted hepatitis B virus infection to all susceptible recipients, half of whom showing clinical symptoms. The remaining three infectious donors were HBs-Ag-negative, yet were icterogenic to 10% to 47% of recipients. Testing of serum samples from these recipients with hepatitis showed no evidence of hepatitis B virus or hepatitis A virus infection. This study and other recent evidence suggest that there is a third type of human viral hepatitis--non-A, non-B hepatitis--which is due to a transmissible agent and may well be associated with a chronic carrier state.
 ...
PMID:Transmission of non-A, non-B hepatitis. 19 5

Resulting directly from the discovery of virus-related antigens, rapid progress has marked the last decade of viral hepatitis research. The hepatitis B virion has been tentatively identified as a DNA virus with an endogenous DNA polymerase, and new serological markers for type B hepatitis have been discovered. Hepatitis A antigen has been identified on a virus-like particle thought to be the hepatitis A virion. Progressively more sophisticated assays for hepatitis antigens and antibodies have been applied to the study of viral hepatitis epidemiology and biochemical-biophysical characterization of the agents. Most recently, knowledge learned from such studies has been exploited to develop a prototype non-infectious but immunogenic hepatitis B vaccine using hepatitis B surface antigen (HBsAg) purified in large quantities from chronic HBsAg carriers. Especially exciting is the prospect, suggested by serological studies of viral hepatitis, that hepatitis viruses besides hepatitis A and B viruses will be identified.
 ...
PMID:Recent advances in the identification of hepatitis viruses. 19 74

The clinicopathologic features of 26 cases of hepatocellular carcinoma (HCC) surrounded by a grossly distinct capsule-like fibrous tissue were studied. The frequency of this type was 10.3% among autopsy cases of HCC. The mean age of the patients was 64.1 years, which was significantly older compared with that of 143 cases of nonencapsulated HCC. Hepatitis-B surface antigen in serum was positive in 18.7% of the cases studied, the positivity rate being lower than that of HCC in general. Histologically, the tumor was relatively well differentiated and the capsule was the product of slow expanding growth. Intravenous tumor invasion was less frequent compared with other types of HCC. Clinically, celiac angiography proves to be a most useful diagnostic method; a thick capsule may be demonstrated as a thin radiolucent rim around the mass. The clinical course from the early stage is protracted and, if detected early, this type of HCC may be removed surgically.
 ...
PMID:Clinicopathologic features of encapsulated hepatocellular carcinoma: a study of 26 cases. 19 91

The chief causes of liver disease in Ethiopia are reviewed, considering hospital data on admissions for hepatitis, cirrhosis, ascites and hepatoma. Liver diseases account for 11.4% of all medical admissions in 3 medical wards in Addis Ababa. The causes are viral hepatitis, post- hepatic and post necrotic and mixed cirrhosis and hepatocellular carcinoma. Alcoholic cirrhosis is rare. Viral hepatitis with shivering, rigor and fever and elevated direct bilirubin levels are common in Ethiopians, especially in child-bearing women. The hepatitis B surface antigen (HBsAg) is often associated with hepatitis. The disease may be transmitted by several species of mosquitoes, placental transmission, or feces, urine, saliva or semen. Blood products are not screened for hepatitis B. Cirrhosis is common, and causes significant mortality, usually from esophageal varices and hepatic coma. Chronic active hepatitis patients may live for a time, especially if they are near a hospital and are treated with steroids. In Ethiopia presenting symptoms for hepatoma are anorexia, weight loss, persistent, burning, right upper quadrant pain, and a hard, nodular, tender RUQ mass. Over 5% of malignancies seen are primary hepatocellular carcinomas. 50% have HBsAG, compared to 3.8% of controls. 65% have alpha-fetoglobulins. It is suggested that some viral hepatitis cases progress to cirrhosis, of which some go on to hepatocellular carcinoma. Herbal medicines, aflatoxins and other toxins may also contribute to liver disease.
 ...
PMID:Current views on liver diseases in Ethiopia. 20 62


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>